Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
Holding GANX?
Track your performance easily
GANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.89 - $5.33
Previous Close$1.62
Volume166.11K
Average Volume (3M)387.37K
Market Cap
$46.95M
Enterprise Value$26.84M
Total Cash (Recent Filing)$16.94M
Total Debt (Recent Filing)$807.57K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 20, 2025EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding26,525,068
10 Day Avg. Volume256,423
30 Day Avg. Volume387,369
Standard Deviation0.21
R-Squared0.00580
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.84
Price to Sales (P/S)826.81
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit486.44
Enterprise Value/Ebitda-1.25
Forecast
1Y Price Target
$7.40Price Target Upside318.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Gain Therapeutics News
PremiumCompany Announcements
Gain Therapeutics Advances Parkinson’s Therapy Development
PremiumPre-Earnings
Is GANX a Buy, Before Earnings?
PremiumCompany Announcements
Gain Therapeutics Excels in Neurodegenerative Drug Trials
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company has sufficient capital to fund operations through its next key event in mid-2025.
Safety And TolerabilityGT-02287 was safe and generally well-tolerated with no serious adverse events observed across all age groups.
Therapeutic PotentialGT-02287 holds promise as a lead treatment for Parkinson’s disease, with potential neuroprotective benefits demonstrated in preclinical models.
Bears Say
Clinical Development RisksThere are risks such as delays in advancing preclinical candidates into clinical studies and unexpected safety issues, which could negatively impact the company's progress.
Financial PerformanceThe company reported a net loss of $0.42 per share, significantly higher than the forecasted net loss of $0.21 per share, due to higher-than-expected operating expenses.
Stock ValuationThe price target for the stock has been reduced from $10 to $5, due to dilution from financing and a slightly higher discount rate.
---
Ownership Overview
4.90% Insiders
1.32% Mutual Funds
3.61% Other Institutional Investors
89.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $0.89 and its highest was $5.33 in the past 12 months.
What is Gain Therapeutics’s market cap?
Currently, no data Available
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Mar 20, 2025 which is in 117 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.207 by $0.037.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -$0.19.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 26,525,068 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.207. Following the earnings report the stock price went up 5.747%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Among the largest hedge funds holding Gain Therapeutics’s share is Greenlight Capital Inc. It holds Gain Therapeutics’s shares valued at 1M.
---
Gain Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.40 (318.08% Upside)
$7.40 (318.08% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 334.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.73%
12-Months-Change
Fundamentals
Return on Equity
-263.14%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
---
GANX Stock 12 Month Forecast
Average Price Target
$7.40
▲(318.08% Upside)
Technical Analysis
Best Analysts Covering GANX
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-23.23%
reiterated a buy rating 4 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -23.23% per trade.
---